 |
BioWorld-Insight-2003-03-10
Stock Winners and Losers For The Week
AIDS Controversy Alive As Before; This Time, Phase III Data And Race
Talk about a hard call.
Investors may have been quick to attach their unmistakable meaning to last month's disclosure by VaxGen Inc. of disappointing Phase III results for its HIV vaccine - the company's stock value nosedived by 47.3 percent - but the scientific world was far from convinced a disaster had taken place.